SEC Comment Letter for Oncotelic Therapeutics, Inc. (OTLC) (CIK 0000908259) (OTLC) — Apr 6, 2009

Oncotelic Therapeutics, Inc. (OTLC) (CIK 0000908259)
Date: April 6, 2009 · CIK: 0000908259 · Accession: 0000000000-09-017702

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

April 6, 2009

Author

Jeffrey P. Riedler

Form

UPLOAD

Company

Oncotelic Therapeutics, Inc. (OTLC) (CIK 0000908259)

Letter

Mail Stop 6010 April 6, 2009 James B. Murphy Vice President and Chief Financial Officer OXiGENE, Inc. 230 Third Avenue Waltham, MA 02451 Re: OXiGENE, Inc. Schedule 14A Filed March 25, 2009 File No. 0-21990

Dear Mr. Murphy: We have completed our review of your preliminary proxy statement on Schedule 14A and have no further comments at this time.

Sincerely,
J e f f r e y P . R i e d l e r A s s i s t a n t D i r e c t o r

Show Raw Text

Mail Stop 6010                                                                                                   April 6, 2009   James B. Murphy Vice President and Chief Financial Officer OXiGENE, Inc. 230 Third Avenue Waltham, MA 02451
 Re: OXiGENE, Inc.
  Schedule 14A
  Filed March 25, 2009   File No. 0-21990

Dear Mr. Murphy:
  We have completed our review of  your preliminary proxy statement on
Schedule 14A and have no further comments at this time.

Sincerely,

          J e f f r e y  P .  R i e d l e r          A s s i s t a n t  D i r e c t o r

cc: Asya S. Alexandrovich  Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
One Financial Center Boston, MA 02111

SecProbe.io